1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Continuous Renal Replacement Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of acute kidney injury (AKI) and chronic kidney diseases (CKD)
5.1.1.2. Availability of improved CCRT systems for pediatric and neonatal patients
5.1.2. Restraints
5.1.2.1. High cost of continuous renal replacement therapy procedure
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for enhanced safety and efficacy of CRRT
5.1.3.2. Favorable government approvals for CRRT machines and techniques
5.1.4. Challenges
5.1.4.1. Technical complications associated with continuous renal replacement therapy
5.2. Market Segmentation Analysis
5.2.1. Product: Growing prevalence toward acute kidney injury (AKI) boosting a need for CRRT devices for seamless treatment procedures
5.2.2. Modality: Utilization of continuous venovenous hemodiafiltration for liberal fluid management in renal therapies
5.2.3. Age Group: Differing CRRT requirements among pediatric population
5.2.4. Indication: Growing adoption of non-renal indications in extracorporeal renal therapies
5.2.5. End User: Increasing uses of CRRT devices in hospitals to cater a patients need
5.3. Market Trend Analysis
5.3.1. Established companies in the North America receiving favorable government approvals for CRRT and their potential expansion in the South American market
5.3.2. Growing number of renal patients in Asia leads to an increased need for continuous renal replacement therapies
5.3.3. Supportive government policies and financial initiatives from established vendors for the kidney health contributed to CRRT advancement across EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Continuous Renal Replacement Therapy Market, by Product
6.1. Introduction
6.2. CRRT Systems
6.3. Dialysates & Replacement Fluids
6.4. Disposables
6.5.1. Bodyline sets & tubes
6.5.2. Hemofilters
7. Continuous Renal Replacement Therapy Market, by Modality
7.1. Introduction
7.2. Continuous Venovenous Hemodiafiltration
7.3. Continuous Venovenous Hemodialysis
7.4. Continuous Venovenous Hemofiltration
7.5. Slow Continuous Ultrafiltration
8. Continuous Renal Replacement Therapy Market, by Age Group
8.1. Introduction
8.2. Adults
8.3. Pediatrics
9. Continuous Renal Replacement Therapy Market, by Indication
9.1. Introduction
9.2. Non-renal
9.3. Renal
10. Continuous Renal Replacement Therapy Market, by End User
10.1. Introduction
10.2. Dialysis Clinics
10.3. Homecare
10.4. Hospitals
11. Americas Continuous Renal Replacement Therapy Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Continuous Renal Replacement Therapy Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Continuous Renal Replacement Therapy Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Agreement, Collaboration, & Partnership
14.3.1.1. Rockwell Medical Announces 3-Year Co-Promotional Collaboration with B. Braun Medical
14.3.1.2. Nuwellis, DaVita partner on ultrafiltration therapy pilot program
14.3.1.3. Baxter, Miromatrix Partner on Liver Failure Research
14.3.1.4. SeaStar Medical, Nuwellis Partner on Kidney Injury Treatment
14.3.1.5. Spectral Medical Announces Strategic Joint Venture with Infomed to Accelerate Commercialization of DIMI and SAMI Dialysis Devices.
14.3.2. New Product Launch & Enhancement
14.3.2.1. PBMC Launches New Renal Therapy Option for Dialysis Patients
14.3.3. Award, Recognition, & Expansion
14.3.3.1. B. Braun Receives FDA Clearance for AQUAbase nX Reverse Osmosis System
14.3.3.2. Quanta Receives FDA 510(k) Clearance for Expanded Indication of Continuous Renal Replacement Therapies
14.3.3.3. Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Anjue Medical Equipment Co., Ltd.
15.1.2. Asahi Kasei Medical Co., Ltd.
15.1.3. B. Braun SE
15.1.4. Baxter International Inc.
15.1.5. Biomedica Medizinprodukte GmbH
15.1.6. Braun & Co. Limited
15.1.7. CytoSorbents Corporation
15.1.8. DIAMED Medizintechnik GmbH
15.1.9. Fresenius Medical Care AG & Co. KGaA
15.1.10. Infomed SA
15.1.11. Joline GmbH & Co. KG
15.1.12. Medites Pharma spol. s.r.o
15.1.13. Medtronic PLC
15.1.14. Miromatrix Medical Inc.
15.1.15. Nextkidney B.V.
15.1.16. Nikkiso Co., Ltd.
15.1.17. Ningbo Tianyi Medical Devices Co., Ltd.
15.1.18. Nipro Corporation
15.1.19. Nuwellis, Inc.
15.1.20. Quanta Dialysis Technologies Limited
15.1.21. SB-KAWASUMI LABORATORIES, INC.
15.1.22. Shionogi & Company, Limited
15.1.23. Sphingotec GmbH
15.1.24. SWS Hemodialysis Care Co. Ltd.
15.1.25. Thermo Fisher Scientific Inc.
15.1.26. Toray Medical Co., Ltd. by Toray Industries, Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
